Tumor-specific major histocompatibility-II expression predicts benefit to anti-PD-1/L1 therapy in patients with HER2-negative primary breast cancer

CONCLUSIONS: Tumor-specific MHC-II has strong candidacy as a specific biomarker of anti-PD-1/L1 immunotherapy benefit when added to standard NAC in HER2-negative breast cancer. Combined with previous studies in melanoma, MHCII has the potential to be a pan-cancer biomarker. Validation is warranted in existing and future Phase II/III clinical trials in this setting.PMID:34315723 | DOI:10.1158/1078-0432.CCR-21-0607

Source: Clinical Cancer Research - July 28, 2021 Category: Cancer & Oncology Authors: Paula I Gonzalez-Ericsson Julia D Wulfkhule Rosa I Gallagher Xiaopeng Sun Margaret L Axelrod Quanhu Sheng Na Luo Henry Gomez Violeta Sanchez Melinda Sanders Lajos Pusztai Emanuel F Petricoin Kim Rm Blenman Justin M Balko I-Spy Trial Team Source Type: research